Ascension finalized its $3.9 billion acquisition of Amsurg after the Federal Trade Commission cleared the transaction, ending the antitrust review that had stalled the deal, HealthExec reported.

The transaction gives Ascension a national network of freestanding ambulatory surgery centers.

HealthExec did not identify the conditions the FTC attached to its clearance or any required divestitures.

What does the FTC agreement require?

Standard consent orders in hospital and physician-service deals typically include structural divestitures, behavioral restrictions on information-sharing between overlapping sites, or a memorandum closing the inquiry without binding conditions.

Any required facility sales, geographic carve-outs, or informational firewalls will surface in the FTC's public docket and the Federal Register once filed.

The HealthExec reporting does not disclose which remedy path the commission took.

Why does the deal matter?

Ambulatory surgery centers have absorbed a growing share of routine procedures over the past decade, reimbursed at facility rates well below hospital outpatient rates.

Payors have driven that shift. Insurers steer volume to lower-cost settings through site-of-service differentials on their fee schedules. Hospitals see outpatient migration as a release valve on inpatient costs and a hedge against declining inpatient volumes.

Acquiring Amsurg gives Ascension a national footprint in that lower-cost setting and shifts some volume away from higher-cost hospital sites.

The combination also reshapes payor negotiations. An integrated system with hospital, physician, and ASC reach can bargain across care settings in a way independent operators cannot.

Amsurg brings consolidated payor contracts, specialty device and anesthesia supply relationships, and an established referral network onto a single platform with Ascension.

The $3.9 billion price tag sets a valuation benchmark across the sector. Private equity-backed ASC operators have watched the review closely as a signal of where the commission draws competition lines in outpatient care.

What changes for ASC competitors

Clearance removes a regulatory overhang that hung over the segment since the deal's announcement.

Comparable transactions paused for FTC review now face a less uncertain path.

The agency's clearance of a $3.9 billion ASC deal narrows the set of transactions the commission views as presumptively anti-competitive.

Amsurg's specialty surgical mix concentrates specialist referral patterns inside Ascension.

Independent specialist groups in overlapping markets will see a referral channel that funnels cases into Amsurg's centers first.

Sector consolidation has accelerated across the past decade. The clearance does not by itself revive that pace, but it removes one unusually large deal from the FTC's active review file.

What the broader FTC push signals

The FTC has routinely challenged hospital consolidation and physician rollups. Behavioral remedies have become the agency's preferred tool where structural divestitures are impractical.

Prior FTC actions against hospital mergers have stretched across several states, with orders typically running ten years. Amsurg clearance, conditional or not, leaves the segment with one of the larger hospital-system ASC combinations cleared by the commission in recent memory.

What's still undisclosed

HealthExec's account does not spell out the integration timeline, executive appointments at Amsurg, or any integration cost guidance from Ascension's finance team.

Quarterly filings and the next investor update are the realistic next opportunity to confirm those details.

A nonprofit Catholic system structure adds state attorney general review in any market where Ascension already operates hospitals.

Those reviews typically track the FTC's resolution by weeks or months. State-level scrutiny has expanded into a routine second front for nonprofit hospital deals since 2020, often focusing on community-benefit commitments and price caps.